Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.
Cardiology November 25th 2024
Medical Professionals Reference (MPR)
The Epitomee capsule, a novel ingestible device for weight management, has shown promising results in clinical trials, with 55.5% of users losing at least 5% of their baseline body weight at 24 weeks.
Endocrinology, Diabetes, Metabolism September 25th 2024
Cleveland Clinic Journal of Medicine
New guidelines endorse the use of continuous glucose monitors and insulin pumps in hospital settings, potentially improving glycemic control while reducing hypoglycemia risk in noncritically ill patients.
Emergency Medicine August 15th 2024
Journal of the American College of Cardiology (JACC)
The P-WCD demonstrated a clinically significant cutaneous adverse device effect rate of only 2.30%, with no severe adverse events reported, suggesting a favorable safety profile for this novel wearable defibrillator.
Cardiology August 5th 2024
Advancements in diabetes technology, including CGMs and smart insulin devices, are providing significant benefits in patient care, making it essential for clinicians to stay informed and comfortable with these innovations.
Endocrinology, Diabetes, Metabolism July 3rd 2024
Practical Neurology
Noninvasive neuromodulation devices offer effective headache management options with minimal adverse events, providing both acute and preventive treatment capabilities. Understanding their mechanisms and practical uses is crucial for optimizing patient care.
Neurology June 24th 2024